Jun 2026 (Q2 FY26) — Aug 10, 2026
Surgery Partners Q2 FY26 — Strong Same-Facility Growth and Strategic Portfolio Optimization
Read the full callSurgery Partners (SGRY) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Surgery Partners earnings: last reported Mon, 10 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 849 | +2.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 12.0 | −1.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -15.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$14.61 −1.08% · −$0.16
Performance −30.8% 1Y
1Y: $21.11 on 15 Oct 2025 → $14.61. High $22.94 (28 Oct 2025), low $11.49 (27 Mar 2026).
- Previous close
- $14.77
- 52-week range
- $11.49 – $22.94
- One year
- −30.86%
Overview
- Symbol
- SGRY
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Surgery Partners earnings calls (SGRY)
Financials
What the filings say
Net profit, year on year: −500% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 770 | 864 | 776 | 826 | 822 | 885 | 811 | 849 |
| Operating profit | 61 | 127 | 62 | 112 | 106 | 110 | 66 | 102 |
| Operating margin | 7.9% | 14.7% | 8.0% | 13.5% | 12.9% | 12.4% | 8.1% | 12.0% |
| Net profit | -32 | -108 | -38 | -2 | -23 | -15 | -36 | -15 |
| EPS ($ per share) | -0.25 | — | -0.30 | -0.02 | -0.18 | — | -0.28 | -0.12 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Reserves | -247 | -316 | -432 | -503 | -557 | -569 | -737 | -815 |
| Total liabilities | 3,577 | 4,036 | 4,531 | 4,148 | 3,741 | 3,842 | 4,694 | 4,988 |
| Fixed assets | 426 | 523 | 545 | 630 | 877 | 969 | 1,088 | 1,153 |
| Total assets | 4,676 | 5,019 | 5,413 | 6,118 | 6,682 | 6,877 | 7,890 | 8,120 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 145 | 130 | 247 | 87 | 159 | 294 | 300 | 274 |
| Cash from investing | -129 | -85 | -88 | -332 | -308 | -226 | -488 | -247 |
| Cash from financing | -6 | -136 | 67 | 316 | 42 | -155 | 262 | -57 |
| Net cash flow | 9 | -92 | 225 | 72 | -107 | -87 | 74 | -30 |
| Capital expenditure | -40 | -74 | -43 | -58 | -81 | -89 | -90 | -79 |
| Free cash flow | 105 | 56 | 204 | 30 | 78 | 205 | 210 | 196 |
Insider filings
39 filings between Jan 13, 2026 and Aug 18, 2026.
Open market
decisions to buy or sellPurchases
$161.2K
1 purchase by 1 insider
Sales
$1.28M
12 sales by 6 insiders
Compensation
not trading decisions- 26
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Evans Jason Eric | — | $412.4K | Mar 16, 2026 |
| Doherty David T | — | $312.5K | Mar 16, 2026 |
| Baldock Jennifer | — | $214.5K | Mar 12, 2026 |
| Brittenham Marissa | — | $166.2K | Mar 13, 2026 |
| DeLuca Teresa | $161.2K | — | Aug 18, 2026 |
| Burkhalter Danielle | — | $149.7K | Mar 13, 2026 |
| Webb William Trenton | — | $28.7K | Mar 6, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 18, 2026 | DeLuca Teresa Director | Purchase | 11,250 | $161.2K |
| Jun 18, 2026 | HENDRIX BLAIR E Director | Award | 34,364 | $500.0K |
| Jun 5, 2026 | Dean Lloyd H Director | Award | 11,670 | $160.0K |
| Jun 5, 2026 | ADLERZ CLIFFORD G Director | Award | 11,670 | $160.0K |
| Jun 5, 2026 | TURNER BRENT Director | Award | 11,670 | $160.0K |
| Jun 5, 2026 | DeLuca Teresa Director | Award | 11,670 | $160.0K |
| Jun 5, 2026 | Deane John A Director | Award | 11,670 | $160.0K |
| Jun 5, 2026 | Forese Laura L Director | Award | 11,670 | $160.0K |
| Jun 5, 2026 | HENDRIX BLAIR E Director | Award | 11,670 | $160.0K |
| Mar 16, 2026 | Evans Jason Eric Chief Executive Officer | Sale | 20,400 | $254.4K |
| Mar 16, 2026 | Doherty David T Chief Financial Officer | Sale | 8,867 | $110.8K |
| Mar 13, 2026 | Brittenham Marissa Chief Strategy Officer | Sale | 3,657 | $45.9K |
| Mar 13, 2026 | Burkhalter Danielle Chief Human Resources Officer | Sale | 3,469 | $44.5K |
| Mar 12, 2026 | Baldock Jennifer Chief Admin & Dev Officer | Sale | 5,798 | $76.4K |
| Mar 6, 2026 | Webb William Trenton American Group President | Sale | 272 | $3.8K |
| Mar 6, 2026 | Burkhalter Danielle Chief Human Resources Officer | Sale | 7,736 | $105.2K |
| Mar 6, 2026 | Baldock Jennifer Chief Admin & Dev Officer | Sale | 10,082 | $138.1K |
| Mar 6, 2026 | Doherty David T Chief Financial Officer | Sale | 14,574 | $201.7K |
| Mar 6, 2026 | Brittenham Marissa Chief Strategy Officer | Sale | 8,785 | $120.4K |
| Mar 6, 2026 | Evans Jason Eric Chief Executive Officer | Sale | 11,462 | $158.1K |
| Mar 5, 2026 | Baldock Jennifer Chief Admin & Dev Officer | Award | 42,523 | $600.0K |
| Mar 5, 2026 | Oppenheimer Justin Robert COO & National Group President | Award | 42,523 | $600.0K |
| Mar 5, 2026 | Brittenham Marissa Chief Strategy Officer | Award | 17,717 | $250.0K |
| Mar 5, 2026 | Brittenham Marissa Chief Strategy Officer | Award | 16,363 | $230.9K |
| Mar 5, 2026 | Brittenham Marissa Chief Strategy Officer | Award | 9,150 | $129.1K |
| Mar 5, 2026 | Webb William Trenton American Group President | Sale | 1,794 | $24.9K |
| Mar 5, 2026 | Webb William Trenton American Group President | Award | 20,454 | $288.6K |
| Mar 5, 2026 | Webb William Trenton American Group President | Award | 11,438 | $161.4K |
| Mar 5, 2026 | Burkhalter Danielle Chief Human Resources Officer | Award | 17,717 | $250.0K |
| Mar 5, 2026 | Burkhalter Danielle Chief Human Resources Officer | Award | 16,363 | $230.9K |
| Mar 5, 2026 | Burkhalter Danielle Chief Human Resources Officer | Award | 9,150 | $129.1K |
| Mar 5, 2026 | Baldock Jennifer Chief Admin & Dev Officer | Award | 40,909 | $577.2K |
| Mar 5, 2026 | Baldock Jennifer Chief Admin & Dev Officer | Award | 22,875 | $322.8K |
| Mar 5, 2026 | Doherty David T Chief Financial Officer | Award | 56,697 | $800.0K |
| Mar 5, 2026 | Doherty David T Chief Financial Officer | Award | 54,545 | $769.6K |
| Mar 5, 2026 | Doherty David T Chief Financial Officer | Award | 30,501 | $430.4K |
| Mar 5, 2026 | Evans Jason Eric Chief Executive Officer | Award | 141,743 | $2.00M |
| Mar 5, 2026 | Evans Jason Eric Chief Executive Officer | Award | 136,363 | $1.92M |
| Jan 13, 2026 | Oppenheimer Justin Robert COO & National Group President | Award | 77,736 | $1.25M |
| Sep 4, 2025 | Bane Harrison R. National Group President | Sale | 5,726 | $128.7K |
| Sep 4, 2025 | Bane Harrison R. National Group President | Sale | 3,613 | $81.2K |
| Aug 11, 2025 | DeLuca Teresa Director | Sale | 20,018 | $455.2K |
| Aug 11, 2025 | Maryland Patricia Anne Director | Sale | 0 | $0 |
| Aug 8, 2025 | Doherty David T Chief Financial Officer | Sale | 47,491 | $1.11M |
| Jun 10, 2025 | ADLERZ CLIFFORD G Director | Award | 6,861 | $160.0K |
| Jun 10, 2025 | Deane John A Director | Award | 6,861 | $160.0K |
| Jun 10, 2025 | TURNER BRENT Director | Award | 6,861 | $160.0K |
| Jun 10, 2025 | HENDRIX BLAIR E Director | Award | 6,861 | $160.0K |
| Jun 10, 2025 | Forese Laura L Director | Award | 6,861 | $160.0K |
| Jun 10, 2025 | DeLuca Teresa Director | Award | 6,861 | $160.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Surgery Partners, Inc.
Free account. Everything above stays public.
Write why you follow Surgery Partners, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading